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Abstract
Introduction and hypothesis Macroplastique® (polydime-
thylsiloxane injection) is a minimally invasive urethral bulk-
ing agent with global clinical literature describing its use
over 20 years. This study critically assessed the safety and
effectiveness outcomes for adult women treated with Mac-
roplastique for stress urinary incontinence (SUI) through a
systematic review and meta-analysis.
Methods A systematic review of the scientific literature
from 1990 to 2010 was conducted in accordance with the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement to quantitatively sum-
marize the safety and effectiveness of Macroplastique for
female SUI. A total of 958 patients from 23 cohorts were
eligible for inclusion and were analyzed. Random-effects
models were used to estimate the improvement and cure
rates following treatment at three time periods: short-term
(<6 months), mid-term (6–18 months), and long-term
(>18 months). Expanded models assessed the effect of rein-
jection rate on successful treatment outcomes. Adverse
event rates were aggregated and reported.
Results Improvement rates were 75 % [95 % confidence
interval (CI), 69–81] in the short-term, 73 % (95 % CI,
62–83) in the mid-term, and 64 % (95 % CI, 57–71) long-
term. Cure/dry rates were 43 % (95 % CI, 33–54), 37 %
(95 % CI, 28–46), and 36 % (95 % CI, 27–46) over the same
respective follow-up periods. Higher study reinjection rates
were associated with improved long-term SUI outcomes. No
serious adverse events were reported.
Conclusions This quantitative review supports Macroplas-
tique as an effective, durable, and safe treatment option for
female SUI. Meta-analytic evidence suggests that long-term
therapeutic benefit is frequently maintained, with some patients
requiring reinjection.
Keywords Long-term effectiveness . Macroplastique .
Meta-analysis . Randomized controlled trial . Silicone
injection . Stress urinary incontinence
Introduction
Stress urinary incontinence (SUI) is a socially, emotionally,
and physically devastating condition affecting millions of
women worldwide. SUI is self-reported in up to 25 % of the
adult female population in the United States [1]. Standard
treatments include pelvic floor muscle exercise regimes,
biofeedback, urethral slings, tension-free vaginal tapes
(TVT), and urethral bulking agents (UBAs). Midurethral
slings are the most frequently performed and effective sur-
gical intervention for SUI. UBAs have been recommended
by the American Urology Association for patients who do
not wish to undergo a more invasive surgery, elderly
patients, and patients at higher risk for anesthetic complica-
tions [2]. Guidance from the Society of Obstetricians and
Gynaecologists of Canada Urogynaecology Committee, the
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American Congress of Obstetricians and Gynecologists, and
the National Institute for Health and Clinical Excellence
(NICE), among others, directs patients with significantly
decreased urethral mobility and/or patients who have failed
appropriate conservative therapy to consider periurethral
bulking agents as one of several treatment options [3–5].
In 2011, glutaraldehyde-treated bovine collagen (Conti-
gen®, CR Bard), the UBAwith the longest history of use for
female SUI, was withdrawn from worldwide availability,
posing a pressing need for the urological community to
evaluate alternative UBAs. New synthetic UBAs were de-
veloped; however, several—such as polytetrafluoroethy-
lene, dextranomer/hyaluronic acid, and ethylene vinyl
alcohol copolymer—were subsequently withdrawn or dis-
continued for safety or efficacy concerns. Currently, carbon-
coated beads, calcium hydroxylapatite (CaHA), and poly-
dimethylsiloxane are marketed to treat female SUI in the
United States, whereas autologous cellular therapy, autolo-
gous fat, and autologous ear chondrocytes lack sufficient
data on efficacy and safety and are considered investigation-
al. Continence outcomes from randomized controlled trials
of UBAs suggest that the efficacy of carbon-coated spheres,
CaHA, and polydimethylsiloxane is similar to cross-linked
collagen [6–8].
Polydimethylsiloxane (Macroplastique®, Uroplasty, Inc.,
Minnetonka, MN, USA) has a long history in the treatment
of female SUI, primarily in Europe, where it has been used
since 1991 and is the leading UBA outside the United
States. Macroplastique is indicated to treat SUI primarily
due to intrinsic sphincter deficiency (ISD). [Medicare, a
federal program in the United States that provides for certain
health care expenses for people ≥65, defines ISD in women
with SUI as abdominal leak point pressures (ALPP) of
≤100 cm H2O without urethral hypermobility.] Macroplas-
tique is nonallergenic, supplied in a ready to use form, and
may be carried out in an office setting under local anesthe-
sia. Macroplastique is comprised of highly textured silicone
elastomer implants suspended in a polyvinylpyrrolidone
(PVP) carrier matrix (Fig. 1). Macroplastique is implanted
at several positions around the urethra, under direct vision
with a cystoscope, approximately 1 cm distal to the bladder
neck to reduce urine leakage from the bladder by bulking
and coapting the urethral tissue left open by the weakened
sphincter. The PVP carrier matrix is exchanged for tissue
fluids containing host fibroblasts. The large, heavily textured
elastomer implants are conducive to tissue in-growth, agglom-
erating and creating a bolus surrounded and infiltrated by host
collagen. The fibrous encapsulation of the bolus anchors it
within the space between the lamina propria and the urethral
muscularis, preventing subsequent implant movement or mi-
gration. After implantation, the PVP carrier is resorbed by the
reticuloendothelial system and excreted via glomerular filtra-
tion without being metabolized.
In 2003, a systematic review of Macroplastique concluded
too few prospective, randomized studies had been conducted
to reach definitive conclusions about its effectiveness [9].
Since then, a randomized controlled trial (RCT) comparing
the effectiveness of Macroplastique to collagen was carried
out [8], leading to marketing approval in the United States in
2006. Additionally, three other randomized studies comparing
Macroplastique to pelvic floor muscle exercise therapy, pubo-
vaginal sling surgery, and porcine dermal implant injection
have been published [10–12]. These trials are complemented
by several prospective studies of small cohorts and descriptive
reports from clinical practice.
The goal of our study was to systematically review the
scientific literature and meta-analyze Macroplastique treat-
ment outcomes for treatment of adult female SUI over time.
Additionally, we sought to investigate the effect of reinjection
rates on improvement and cure rates and to aggregate reports
of adverse events (AEs) to characterize treatment safety.
Methods
Study design and data sources
This systematic review and meta-analysis was conducted
using the guidelines set forth in the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement [13]. We searched Ovid MEDLINE,
PubMed, and the Cochrane Library databases from January
1990 to June 2010 and checked the references of systematic
reviews for studies reporting Macroplastique treatment in
women with SUI. Search terms were all pairwise combina-
tions of the following terms: “Macroplastique,” “stress uri-
nary incontinence,” and “silicone injection,” as well as
“Macroplastique” alone.
Inclusion and exclusion criteria
Two statistical consultants (The Integra Group, Brooklyn
Park, MN, USA) evaluated articles independently and in
Fig. 1 Scanning electron microscopy image of Macroplastique
implants
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duplicate, and disagreements were resolved by consensus.
Candidates for inclusion were peer-reviewed publications of
RCTs and prospective, observational, or cohort studies
reporting treatment outcomes and/or AEs related Macro-
plastique treatment for female SUI. Case studies, letter
reports, reviews, and animal studies were excluded. To
avoid bias, we also excluded statistics for which 25 % of
the sample was lost to follow-up. In cases in which data
from a particular study sample appeared in more than one
publication, the article with the most complete follow-up
data was used. We imposed no search restrictions based on
language.
Data extraction and quality assessment
Data were extracted into a database by the second author and
were double-checked independently by another statistical con-
sultant for accuracy. The metric for assessing treatment effi-
cacy varied between studies (e.g., Stamey incontinence grade,
physician and patient ratings of improvement, pad weight), so
we characterized treatment success according to the propor-
tion of the study sample “cured” (i.e., defined as no symptoms
of SUI, Stamey grade 0, or dryness) or “improved” (i.e.,
defined as cured or significant improvement in symptoms
from baseline). In cases in which physician and patient assess-
ments were reported, physician evaluations were used.
Follow-up periods from published studies varied from 1
month to >5years. Improvement and cure rates were classi-
fied into three time strata: short-term (<6 months), mid-term
(6–18 months), and long-term (>18 months). The proportion
of patients improved and cured was meta-analyzed for each
time stratum. For retrospective studies in which improve-
ment and cure rates were not collected at a prespecified
time, we used the sample’s mean follow-up time to classify
the time stratum. Where available, data on reinjection rates
within studies were extracted to explore potential relation-
ships with treatment success. Reported AEs were also
extracted; however, clinical definitions varied too greatly
between studies for meta-analysis. We report the median
value and interquartile range (IQR) for AE rates across
studies.
We evaluated methodological quality of all articles meeting
inclusion criteria in several domains:
1. description of the study population and selection
method;
2. description of potential confounders (e.g., urethral hyper-
mobility and history of incontinence surgery);
3. reporting of study location(s) and enrollment/treatment
dates;
4. description of treatment exposure (e.g., injection meth-
od, average volume injected, number of treatments,
reinjection rates);
5. appropriate statistical analysis;
6. description of randomization, blinding, and Institutional
Review Board approval, where applicable;
7. description of loss to follow-up and the handling of
missing data;
8. reporting of AEs.
Statistical analysis
Significant heterogeneity between study outcomes was an-
ticipated due to the small sample sizes of several studies and
different designs. Therefore, we used random-effects (RE)
linear regression models to estimate the proportions of the
sample improved and cured at each of the three time strata.
We applied an arcsine square-root transformation to stabilize
variance estimates where necessary to ensure confidence
limits were not estimated to be <0 % or >100 % [14].
Results from models using the arcsine-transformed data
are reported back-transformed, so interpretation is identical
for all models regardless of data transformation. Forest plots
show study-specific and model estimates for each endpoint
and indicate whether the arcsine transformation was applied.
Expanded RE models were used to explore the effect of
study reinjection rates on improvement and cure rates. Study
heterogeneity, which describes the variation between study
outcomes not due to chance variation, was measured using
I2 (the percent of total variability in study outcomes attrib-
utable to heterogeneity) and was tested for significance
using Cochran’s Q test. Funnel-plot asymmetry, an indicator
of potential reporting bias, was assessed with Egger’s test.
Statistical analyses were conducted with the metafor pack-
age [15] for R, version 2.14.1 (R Development Core Team,
2011).
Results
Study and sample characteristics
Sixty-five unique candidate articles were retrieved from all
searches, and 23 patient cohorts from 24 published articles
[8, 10–12, 16–35] met inclusion criteria and were included
in the meta-analysis, for a total of 958 patients. Four patient
cohorts were from randomized studies [8, 10–12], nine were
prospective observational studies [16–23, 32], and ten were
retrospective studies of clinical practice [24–30, 33–35]. We
did not include 27 review papers, four case reports, nine
studies that did not use Macroplastique, and one animal
study. We excluded long-term data from three papers with
insufficient follow-up [11, 31, 34]. All studies used a tran-
surethral injection technique with either endoscopic injec-
tion or the Macroplastique Implantation System (MIS;
Int Urogynecol J (2013) 24:27–36 29
Uroplasty BV, Geleen, The Netherlands), which is a non-
endoscopic needle guide. Most studies reviewed defined
ISD as maximum urethral pressure (MUP) or maximum
closing urethral pressure (MUCP) ≤20 cm H2O and/or Val-
salva’s leak-point pressure (VLPP/ALPP) <60 cm H2O.
Summaries of each study, including reported AEs and
assessments for risk of bias according to the previously
defined criteria, are presented in Table 1. Median age of
study samples was 59 years (IQR, 54–65). The median
proportion of the study samples that had undergone at least
one previous surgery for urinary incontinence was 42 %
(IQR, 30–70).
Most deviations from the expectation of quality were minor;
however, two studies did not provide an adequate definition of
improvement and cure. Both were included in meta-analyzed
proportions despite contributing outlying data points [23, 25].
Meta-analysis of success and cure rates
Data from 12 studies contributed to the aggregate short-term
improvement rate of 75% [95 % confidence interval (CI), 69–
81; (Fig. 2a)]. Thirteen studies contributed to the short-term
cure rate of 43 % (95 % CI, 33–54; Fig. 2b). Significant
heterogeneity was observed in both short-term improvement
(I2067 %, P00.05) and cure (I2083 %, P<0.001) rates but
not publication bias (both P>0.10).
Data from ten studies contributed to the mid-term improve-
ment rate of 73 % (95 % CI, 62–83; Fig. 3a) and 11 to the cure
rate of 37 % (95 % CI, 28–46; Fig. 3b). Significant heteroge-
neity was detected in mid-term improvement (I2083 %,
P<0.001) and cure (I2072 %, P<0.001) rates but not publi-
cation bias (both P>0.10).
Data from ten studies contributed to the aggregate long-
term improvement rate of 64 % (95 % CI, 57–71; Fig. 4a)
and 11 to the long-term cure rate of 36 % (95 % CI, 27–46;
Fig. 4b). Significant heterogeneity was observed for long-
term improvement (I2056 %, P<0.001) and cure (I2079 %,
P<0.001) rates. Significant funnel plot asymmetry was
detected in the long-term improvement rate, where studies
with larger sampling errors (i.e., smaller sample sizes)
reported lower improvement rates (P00.04). Conversely,
there was a significant trend of studies with larger sampling
errors reporting higher cure rates (P00.003).
Effect of reinjection on improvement and cure rates
Seventeen studies reported reinjection rates for patients who
had not been cured after the first injection and thus offered
reinjections to improve the outcome. Across these 17 stud-
ies, the median reinjection rate was 30 % (IQR 14–37).
Expanded RE models found that higher reinjection rates
were associated with higher improvement rates in long-
term but not short-term or mid-term follow-up (both P>
0.10). On average, in long-term follow-up, 63 % (95 % CI,
56–70) of patients in a cohort with the typical reinjection
rate (30 %) had SUI symptom improvement; each 10 %
increase in the proportion of the sample undergoing repeat
injections was associated with an additional 4 % (95 % CI,
1–7) of the sample having improved in the long term. Study
reinjection rates were not significantly associated with study
cure rates at any time point (all P>0.3).
Adverse events
The median rates for AEs were 7 % (IQR, 5–15) for tem-
porary urinary retention, 7 % (IQR, 4–27) for urge inconti-
nence, 3 % (IQR, 0–8) for urinary tract infections, 50 %
(IQR, 11–79) for temporary dysuria, and 45 % (IQR, 8–64)
for transient hematuria. There were no reports of extrusion,
migration, immune reaction, embolic phenomena, vascular
occlusion, or other serious AEs.
Discussion
This systematic review and meta-analysis of 20 years of
global experience in clinical research and practice indicates
that Macroplastique is a safe and effective urethral bulking
agent for treating women with SUI primarily due to ISD.
Pooled results suggest successful outcomes in the short term
for 75 % and cures for 43 % of patients. Furthermore, our
results suggest that those with initial success frequently sus-
tained therapeutic benefit past 18 months. On average, at the
sample level, 85 % of patients sustained their improvement
and 84 % sustained their cure, attesting to the durability of
Macroplastique therapy. Ghoniem and colleagues followed
for 2 years initially successful 12-month patients from the
122 patients treated in the US Investigation Device Exemption
(IDE) RCT [31]. Though an insufficient number of patients
were followed to include in the our meta-analysis, subcohort
results were consistent with the meta-analyzed results report-
ing that of initially successful patients presenting at 2 years, 56
of 67 patients (84 %) maintained improvement at 2 years and
45 of 67 (67 %) maintained cure.
The long-term reinjection rate was positively associated
with treatment outcome on the study level, supporting the
clinical practice of reinjection to both sustain improvements
and build upon them when the patient is not cured after the
first injection. For example, Henalla et al. reported on 14
patients who initially failed treatment; eight (57 %) were
cured or significantly improved by a second injection [21].
In addition, four patients who were significantly improved
chose to undergo a second injection; three were cured and
one remained significantly improved. Our findings consid-
ered with clinical evidence suggest that Macroplastique
therapy may be approached as a process of treatment and
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re-evaluation, with the option of repeat injections if initial
results are unsatisfactory and with regard to important con-
traindications such as a fragile urethral mucosal lining.
Though their data were too few for quantitative analysis,
a small number of studies reported on patients with SUI of
mixed etiology. In the randomized trial by ter Meulen and
colleagues, 88 % of patients with SUI and hypermobility
(n024) were cured or markedly improved at 12 months
[10]. Findings, however, are mixed, as two studies found
no effect of hypermobility on treatment efficacy [11, 19]
Table 1 Summary of studies included in the meta-analysis
Authors Study
design
No. participants Adverse
event rates
Risk of
bias assessment
Ghoniem et al. [8] Randomized study, blinded 122 24 % urinary tract infection, 12 %
frequency, 9 % dysuria, 7 %
retention, 5 % voiding
No evidence of bias
ter Meulen et al. [10] Randomized prospective
study, unblinded
24 79 % retention, 50 % dysuria,
8 % implant leakage
No evidence of bias
Maher et al. [11] Randomized prospective
study, unblinded
23 9 % urinary tract infections,
4 % voiding
Follow-up at long-term <75 %
Bano et al. [12] Randomized prospective
study, unblinded
24 13 % retention, 1 non-device-
related death
No description of sites and
dates, sample characteristics
Zullo et al. [16] Prospective observational study 27 No major intra- or postoperative
AEs observed
No description of sample
characteristics or reporting
of common AEs
Plotti et al. [17] Prospective observational study 24 No major intra- or postoperative
AEs observed
No description of sample
characteristics or reporting
of common AEs
Zullo et al. [18] Prospective observational study 61 7 % urgency, 3 % urinary tract
infection, 2 % dysuria
No evidence of bias
Tamanini et al. [19], 2006 Prospective observational study 21 100 % dysuria, 14 % retention No evidence of bias
Radley et al. [20] Prospective observational study 56 12 % urinary retention,
6 % urinary tract infection
No evidence of bias
Henalla et al. [21] Prospective observational study 40 18 % retention, 63 % dysuria No evidence of bias reporting
of sample’s mean age.
Barranger et al. [22] Prospective observational study 21 No major intra- or postoperative
AEs observed
No reporting of common AEs
Koelbl et al. [23] Prospective observational study 32 6 % urinary tract infection No description of sample
characteristics or reporting
of common AEs, definition
of “cure” not defined
de Tayrac et al. [32] Prospective study 20 11 % pain, 16 % dysuria,
32 % retention
No evidence of bias
Sander et al. [35] Retrospective study 53 15 % retention, 13 % urge
incontinence, 11 % dysuria
No evidence of bias
Franceschetti et al. [33] Retrospective study 44 Small loss of blood in one
patient due to anesthesia
Reporting of AEs inadequate
Hidar et al. [34] Retrospective study 25 8 % retention, 16 % implant
leakage
Long-term follow-up <75 %
Mourad [24] Retrospective case series study 48 13 % retention No reporting of several
common AEs; reporting
of AEs inadequate
Peeker et al. [25] Retrospective case series study 20 Most patients reported mild
dysuria
Reporting of AEs inadequate
Gürdal et al. [26] Retrospective review study 29 45 % hematuria, 79 % dysuria,
72 % frequency, 3 % retention
No evidence of bias
Soliman and Evans [27] Retrospective review study 68 6 % retention No evidence of bias
Usman and Henalla [28] Retrospective review study 102 7 % retention, 1 % urinary
tract infection
No evidence of bias
Sheriff et al. [29] Retrospective review study 34 12 % retention, 53 % dysuria,
68 % hematuria, 76 %
frequency
No evidence of bias
Harris et al. [30] Retrospective case series study 40 Almost all patients had dysuria Reporting of AEs inadequate
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whereas others found patients with ISD and hypermobility
failed at higher rates than those with ISD alone [16, 17].
More research is required to determine the effectiveness of
Macroplastique for SUI of mixed etiology.
Several randomized studies compared the relative effica-
cy of different UBAs primarily with collagen as the com-
parator. An RCT comparing Macroplastique with collagen
(n0247) observed improvement rates of 62 % and 48 %
Fig. 2 a, b Short-term
(<6 months) improvement rates
(a) and cure rates (b) sorted by
year of publication
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(P<0.001) and cure rates of 37 % and 25 % (P<0.05),
respectively, after 12 months [8]. The improvement rate at
12 months for pyrolytic carbon-coated beads (80 %) was not
inferior to that of collagen (69 %) in a double-blind trial (P0
0.16; n0355) [7]. CaHA was not inferior to collagen in a
single-blind trial (n0296), with improvement rates of 63 %
and 57 % at 12 months, respectively (P00.34) [6]. A smaller
trial of CaHA and collagen (n046) reported 80 % improve-
ment in the CaHA group and 62 % in the collagen group
after a mean of 32 months of follow-up [36]. A single-blind
Fig. 3 a, b Mid-term
(6–18 months) improvement
rates (a) and cure rates (b)
sorted by year of publication
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RCT of dextranomer/hyaluronic acid versus collagen (n0
344) documented 12-month improvement rates of 51.2 %
and 54.5 %, respectively [37]. An RCT of a copolymer of
ethylene vinyl alcohol dissolved in dimethyl sulfoxide com-
pared with collagen (n0249) showed superior 12-month
improvement rates over collagen (76 % v. 55 %; P<0.001)
[38]. A small RCT of Macroplastique and porcine dermal
collagen (n048) reported improvement in 58 % in the
porcine collagen group and 42 % in the Macroplastique
group [12].
Fig. 4 a, b Long-term
(>18 months) improvement
rates (a) and cure rates (b)
sorted by year of publication
34 Int Urogynecol J (2013) 24:27–36
Macroplastique has a strong safety profile over 20 years,
with no record of serious AEs. Importantly, there were no
reports of extrusion, migration, or immune reaction in any of
the papers identified in our systematic review. The most
commonly identified side effects of treatment, transient
dysuria and hematuria, are mild. Less frequent AEs included
temporary urinary retention, temporary urge incontinence,
and urinary tract infection. The RCT comparing Macroplas-
tique with collagen provided the most comprehensive list of
AEs among the reviewed publications: urinary tract infec-
tion (24 %), dysuria and urgency (9 %), frequency (8 %),
and retention (7 %) [8]. These side effects are mild, tran-
sient, and easily managed without long-term sequelae for
the patient compared with more invasive surgical device
procedures, which require long recovery times and an in-
creased risk of serious complications, such as severe pain,
organ perforations, hemorrhage, urethral erosion, and vaginal
extrusion [39].
Macroplastique is typically administered in an office-
based setting with a local anesthetic, providing a simple
and low-risk treatment option for women who are not can-
didates for general anesthesia, women who desire to get
pregnant, and patients who desire a short recovery period
[2]. Our analysis suggests Macroplastique is most appropri-
ate for women who expect a long-term significant improve-
ment in their SUI symptoms but would be satisfied if not
completely cured. A recent study of women’s expectations
from SUI interventions suggests most women would con-
sider their treatment successful if they have significant im-
provement in symptoms (57 %) [40]. In the study of
women’s expectations, 71 % of women preferred a minor
procedure, such as a UBA, TVT, or transobturator tape
(TOT); older women were significantly more likely to
choose an office-based procedure. Other women who may
prefer Macroplastique are those desiring to have more children
or who would prefer a short recovery time [41].
The primary limitation of this meta-analysis is the vari-
ability in design among the included studies. Proportions
and confidence intervals for some studies were observed
both above and below the meta-analyzed result, which led
to significant heterogeneity. Many studies had modest sam-
ples sizes, which may explain between-study variability in
improvement and success rates. This may also suggest that
other factors not accounted for in our analysis, such as
unmeasured characteristics of the patient population, clinical
definitions of cure and improvement, or clinician experi-
ence, may mitigate success rates in these studies. Another
limitation is that the long-term efficacy rates had significant
evidence of potential publication bias. Caution should be
exercised in their interpretation, as the long-term success
rate tended to be higher in larger studies than in smaller
studies, whereas the long-term cure rate tended to be lower
in larger studies. Finally, analyses of reinjection efficacy
were based on a subset of all studies in the meta-analysis
and may not have been adequately powered to detect these
associations.
Four randomized trials were found, but none of the meta-
analyzed statistics were able to synthesize results from all
four studies. Even so, the aggregate statistics agree with and
support the results found in the RCTs, with good short-term
(75 %) and long-term (64 %) efficacy and safety profiles.
Although the studies identified in the systematic review
varied in location, design, and setting, their combined
results describe a 20-year global history of safe and effective
treatment with Macroplastique for adult women with SUI.
Conclusions
Results of this quantitative review support Macroplastique
as an effective and durable treatment option for female SUI.
Meta-analysis of all relevant peer-reviewed literature shows
that Macroplastique largely sustains its therapeutic benefit
in the mid-term and long-term, with some patients requiring
reinjection to attain maximal effects. Macroplastique may be
best suited to women who desire long-term significant im-
provement or cure of their SUI and who prefer a minimally
invasive procedure with low morbidity and short recovery
time.
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